Good afternoon, and welcome to the Synthetic Biologics 2017 Year End Investor Conference Call. [Operator Instructions] Please note, this event is being recorded. At this time, I would like to turn the call over to Vincent Perrone, Director of Corporate Communications at Synthetic Biologics. Vincent?

Thank you, Gally, and good afternoon everyone. Welcome to Synthetic Biologics 2017 year end investor conference call. Today, I'm joined by our Acting CEO and CFO, Steve Shallcross; and our Chief Medical Officer, Dr. Joseph Sliman. Synthetic Biologics issued a press release this afternoon which provided operational highlights and reported our financial results for the full year ending December 31, 2017. The release can be found on the Investors Relations section of our website. During our call today, Steve will provide an operational update on our microbiome focused clinical programs and summarize our financial results. We'll take questions after our prepared remarks. In addition to the phone lines, this call is being streamed live via webcast, which will be archived on our website www.synthethicbiologics.com for 90 days. During this call, we will be making forward-looking statements regarding Synthetic Biologics current expectations and projections about future events. Generally, the forward looking statements can be identified by terminology such as may, should, expects, anticipates, intends, plans, believes, estimates, and similar expressions. These statements are based upon current beliefs, expectations and assumptions and are subject to a number of risks and uncertainties including those set forth in Synthetic Biologics filings with the SEC, many of which are difficult to predict. No forward-looking statements can be guaranteed and actual results may differ materially from such statements. The information on this call is provided only as of the date of this call and Synthetic Biologics undertakes no obligation to update any forward-looking statements contained on this conference call on account of new information, future events or otherwise except as required by law. With that, I'd like to turn the call over to Steve. Steve?

Thanks, Vincent. Good morning everyone and thank you for joining us today. 2017 was an important year for Synthetic Biologics. We announced key advancements for our microbiome focused clinical program targeting critical unmet needs and the prevention of life threatening gut microbiome infections in GI disorders. Both of our lead product candidates, ribaxamase or SYN-004 incentin [ph] are Phase 3 ready. During the year the FDA cleared a Phase 2b/3 adaptive designed pivotal trial intended to further evaluate the efficacy and safety at SYN-010 and towards the end of 2017 we began our discussions with the FDA to design a Phase 3 clinical program for ribaxamase. As a result of these activities, both product candidates are now closer to commercial viability as we continue to evaluate the right path to market for each of these assets. Importantly, we also reinforced our financial foundation managing our expenses throughout the year and raising the additional $12 million in capital during the fourth quarter of 2017. We remain committed to our mission to develop best-in-class microbiome focused products and are excited about the potential of our lead candidates to improve clinical outcomes and quality of life for millions of underserved patients. In 2018, we plan to define an optimal development path for each program that we believe will drive long-term shareholder value. Our two key priorities for 2018 are as follows; first, to continue to work with the FDA to establish the optimal design for the Phase 3 clinical program for SYN-004. And number two, to continue to aggressively evaluate strategic opportunities including partnership or licensing agreements for one or both of our prepared period late stage assets. One of those assets is SYN-004 or ribaxamase, our first-in-class oral enzyme which holds the potential to be a destructive yet simple approach to more…

Thank you, Steve. Gally, we'd like to open the phone line to questions. Would you please describe the procedure to ask questions for our listeners?

So given that we have no questions in the queue, I just want to make a couple of final closing remarks. First of all, I'd like you to know that we clearly understand the value of our assets and that you have my personal commitment and the commitment of our team that we are keenly focused on unlocking that value for our shareholders. And second, we've committed significant outside resources to position ourselves to achieve our two key objectives for the year. Thank you again for your continued support and patience and I look forward to continuing to report back to you on our ongoing progress.

Thank you. This completes Synthetic Biologics 2017 year end investor call.